Applied Cardiac Systems Inc. Company Overview
ACS has been a leading provider of Ambulatory ECG devices (AECG – Holter Monitoring) technology for more than 32 years in U.S. ACS entered into the US External Counterpulsation Therapy marketplace in 2002 market and now claims to have the largest number of active External Counterpulsation (ECP) Therapy customers in the U.S.
ACS experienced immediate success in U.S. External Counterpulsation Therapy marketplace by leveraging the long-time relationships they had developed in Cardiology with their Holter Monitoring systems. Although External Counterpulsation Therapy (ECP) was not familiar to many Cardiologsist in the early 2000’s, ACS was no stranger. ACS was capable of quickly growing their ECP customer base to nearly 30% of the U.S. market-share within the first few years in the industry. This quick growth was executed by providing a high quality ECP device to their existing Holter Monitoring customers at a fraction of the cost of the competition.
After the termination of the distribution agreement with Nicore in 2003, ACS made significant device modifications and began manufacturing their own ECP technology starting with the first Natural Counterpulsation device called NCP-2. The NCP-2 ECP device had notable success against the competition primarily because it offered a few technological advancements critical to the market at that time. The NCP-2 offered a treatment report as well as various user features including Holter Monitoring software that presented a greater value than just an ECP only device. ACS now manufactures (arguably) the most widely sold device in the industry today, the NCP Plus.
ACS takes pride in having developed significant improvements in ECP device technology. They claim to have made several advancements to ECP device technology including system that is more quiet, generates less heat, improves patient comfort, improves system reliability at a lower price.
ACS got into External Counterpulsation Therapy a few years after both Cardiomedics & Vasomedical entered the U.S. market. ACS does not carry many of the badges of honor in the External Countepulsation Therapy marketplace that Vasomedical can claim, but the NCP Series External Counterpulsation devices can take credit for two main proven successes.
1. Technological Advancements of the ACS Model NCP-1 to the later model ACS Model NCP-2 , ACS Model NCP Plus ECP device technology. Improvements in automating the treatment process with software & user interface advancements, enhanced reporting tools, network integration as well as instant remote support through the internet.
2. The competitive success of ACS has made ECP device prices far more affordable for the industry as a whole.
ACS is proven to be a significant player in the U.S External Counterpulsation Therapy marketplace. If you are looking for a company with strength in device technology at a lower cost, ACS may be the right partner for you. For more product features of ACS device technology, download our Free “ECP Product Comparison” or visit our “ECP & EECP® Product Reviews” to read product reviews and see for yourself how ACS device technology stacks up versus the competition.
Legal & Safety Notice
Applied Cardiac Systems has a sound record of manufacturing medical devices in the U.S. for more than 32 years. Although there is no public notices regarding the safety & manufacturing practices of ACS, the competition claims that ACS has documented no proof of any safety accreditations such as a CE Mark™ other than ISO 60601 safety compliance.